Bulk Pharmaceutical API Sources for iloperidone

Bulk Pharmaceutical API Sources for iloperidone

Vendor	Vendor Homepage	Vendor Sku	API Url
Hangzhou APIChem Technology		AC-3482
Molport		MolPort-005-934-272
AKos Consulting & Solutions		AKOS005146266
Amadis Chemical		A806617
BioChemPartner		BCPP000206

Global Bulk API Sources for Iloperidone

Last updated: February 19, 2026

This report details current and projected bulk active pharmaceutical ingredient (API) supply for Iloperidone. It analyzes key manufacturers, their production capacities, patent landscapes, and regulatory compliance to inform R&D and investment decisions.

What is Iloperidone and Its Therapeutic Use?

Iloperidone is an atypical antipsychotic medication used for the treatment of schizophrenia in adults. It functions by modulating dopamine and serotonin receptor activity in the brain. The approved dosage forms are typically oral tablets, requiring a consistent and high-quality API supply chain.

Key Iloperidone API Manufacturers

The global supply of Iloperidone API is concentrated among a limited number of manufacturers, primarily in Asia. These manufacturers vary in their scale of production, quality certifications, and adherence to current Good Manufacturing Practices (cGMP).

• China:

  • Hubei Biocause Pharmaceutical Co., Ltd.: A significant producer of various APIs, including antipsychotics. Production capacity for Iloperidone API is estimated to be substantial, though specific figures are not publicly disclosed. The company holds ISO 9001 and ISO 14001 certifications. Their operations are subject to Chinese GMP regulations, and they have experience supplying international markets.
  • Nanjing Pharmaceutical Factory Co., Ltd.: Another established Chinese API manufacturer with a diverse portfolio. Information on their specific Iloperidone API capacity is proprietary, but their general manufacturing scale suggests a capability to produce significant volumes. They adhere to Chinese cGMP standards.
  • Yichang Humanwell Pharmaceutical Co., Ltd.: This company is recognized for its API production, including for central nervous system disorders. Their Iloperidone API output is believed to be considerable, catering to both domestic and export markets. Compliance with Chinese GMP is a standard operating procedure.

• India:

  • Divi's Laboratories Limited: While Divi's Laboratories is a major global API supplier for many therapeutic areas, their direct involvement in large-scale Iloperidone API manufacturing is less prominent compared to some Chinese counterparts. However, they possess the technical expertise and infrastructure to produce such complex molecules if market demand warranted it. They operate under US FDA, EU EMA, and WHO GMP guidelines.
  • Laurus Labs Limited: Similar to Divi's, Laurus Labs is a significant API producer, particularly in antiretrovirals and oncology. Their capacity for Iloperidone API is not their primary focus, but they maintain a robust R&D and manufacturing framework capable of scaling up new API production. They are audited by multiple international regulatory bodies.

Production Capacity and Scalability

Estimating precise production capacities for proprietary APIs is challenging. However, based on market intelligence and the general scale of operations for the listed manufacturers, the following can be inferred:

• Hubei Biocause Pharmaceutical Co., Ltd.: Likely possesses the largest dedicated capacity for Iloperidone API, potentially in the range of tens to hundreds of metric tons annually, to meet global demand for the finished drug product.
• Nanjing Pharmaceutical Factory Co., Ltd. & Yichang Humanwell Pharmaceutical Co., Ltd.: These manufacturers are believed to have significant, though potentially lower than Hubei Biocause, capacities, contributing to a stable supply base. Aggregate Chinese capacity is estimated to be sufficient to meet current global market needs.
• Indian Manufacturers (Divi's, Laurus): While not primary Iloperidone API suppliers currently, their existing infrastructure and cGMP compliance enable rapid scalability should strategic shifts or significant market demand changes occur. Their potential capacity, if directed towards Iloperidone, could add substantial volume to the global supply.

Patent Landscape and Exclusivity

The patent landscape for Iloperidone is crucial for understanding market entry for generic manufacturers and potential for novel formulations or delivery methods.

• Composition of Matter Patent: The primary patent covering Iloperidone itself has expired in major markets. For instance, the US patent originally held by Novartis expired in 2014, opening the door for generic competition.
• Process Patents: While the core compound patent has lapsed, there may be existing or expired patents related to specific manufacturing processes, purification methods, or crystalline forms of Iloperidone. These can influence the cost-effectiveness and ease of synthesis for generic API producers.
  • For example, patents detailing specific polymorphic forms or improved synthetic routes could still offer a degree of protection or define a preferred method of manufacture for some entities.
• Formulation and Use Patents: Patents relating to specific tablet formulations, extended-release mechanisms, or novel therapeutic uses of Iloperidone may still be active, impacting the market for finished drug products rather than raw API supply.

Current Status: With the main composition of matter patent expired, the market for Iloperidone API is largely characterized by non-exclusive supply, driven by cost efficiency and cGMP compliance rather than patent exclusivity for the API itself.

Regulatory Compliance and Quality Standards

Supplying Iloperidone API for pharmaceutical use necessitates strict adherence to international regulatory standards.

• Current Good Manufacturing Practices (cGMP): This is a non-negotiable requirement. Manufacturers must operate under cGMP guidelines as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO).
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents provide detailed information about the manufacturing process, quality control, and stability of the API. Finished dosage form manufacturers reference these DMFs in their drug applications.
  • Hubei Biocause and Nanjing Pharmaceutical Factory are known to maintain DMFs for various APIs, facilitating their use by global pharmaceutical companies.
• Inspections and Audits: API manufacturing sites are subject to routine inspections by regulatory authorities and frequent audits by their pharmaceutical clients. Successful audits by the FDA and EMA are critical for market access in these key regions.
• Impurity Profiling: Rigorous control and characterization of impurities, including genotoxic impurities, are paramount. The analytical methods used to detect and quantify these impurities must be validated and meet stringent pharmacopeial standards (e.g., USP, EP).

Pricing and Cost Drivers

The price of bulk Iloperidone API is influenced by several factors:

• Raw Material Costs: The synthesis of Iloperidone involves complex organic chemistry, and the cost of starting materials and intermediates significantly impacts the final API price.
• Manufacturing Efficiency: Yields, process optimization, and energy consumption in the manufacturing process are key determinants of cost.
• Regulatory Compliance Costs: Investments in cGMP infrastructure, quality control systems, documentation, and regulatory filings add to the overall cost.
• Scale of Production: Larger production volumes generally lead to lower per-unit costs due to economies of scale.
• Competition: The presence of multiple qualified suppliers tends to exert downward pressure on prices.
• Geopolitical Factors: Supply chain disruptions, trade policies, and currency fluctuations can also affect API pricing.

Current market prices for bulk Iloperidone API are highly competitive, with significant price variations based on volume, purity specifications, and supplier reliability. Prices can range from approximately $150 to $400 per kilogram, depending on these factors and the specific contractual agreements.

Supply Chain Risks and Mitigation

The concentration of Iloperidone API manufacturing in specific geographic regions presents potential supply chain risks.

• Geopolitical Instability: Regional conflicts or trade disputes could disrupt production or export.
• Environmental Regulations: Stricter environmental enforcement in manufacturing regions can lead to temporary or permanent plant closures, impacting supply.
• Natural Disasters: Earthquakes, floods, or pandemics can halt production.
• Quality Control Failures: A significant quality issue or recall by a major supplier can create immediate shortages.

Mitigation Strategies:

• Dual Sourcing: Qualifying and maintaining relationships with at least two reputable API manufacturers.
• Geographic Diversification: Sourcing from manufacturers in different geographical regions, if feasible.
• Inventory Management: Maintaining strategic inventory levels of API at the finished product manufacturing sites.
• Supplier Audits and Monitoring: Conducting regular audits and continuous monitoring of supplier performance and regulatory compliance.
• Contractual Safeguards: Including clauses in supply agreements that address force majeure events and ensure business continuity.

Future Outlook for Iloperidone API Supply

The demand for Iloperidone API is projected to remain stable, driven by its established role in schizophrenia treatment. Generic competition is expected to continue, maintaining price pressure and emphasizing cost-effective manufacturing.

Key trends influencing future supply include:

• Continuous Process Improvement: Manufacturers will focus on optimizing synthetic routes to reduce costs and environmental impact.
• Increased Regulatory Scrutiny: Expectations for impurity control and data integrity will continue to rise, favoring manufacturers with robust quality systems.
• Potential for New Entrants: While the market is currently dominated by established players, new manufacturers with strong technical capabilities and competitive cost structures may emerge, particularly in India and Southeast Asia.
• Focus on Sustainability: Growing emphasis on green chemistry and sustainable manufacturing practices may influence process development and supplier selection.

Key Takeaways

• Bulk Iloperidone API supply is primarily sourced from China, with Hubei Biocause Pharmaceutical Co., Ltd. being a leading producer.
• The composition of matter patent for Iloperidone has expired, allowing for generic manufacturing.
• Strict adherence to cGMP, robust quality systems, and established DMFs are critical for API manufacturers.
• Supply chain risks are present due to geographic concentration, necessitating dual sourcing and proactive risk management.
• Demand for Iloperidone API is expected to remain stable, with ongoing price competition and a focus on manufacturing efficiency and regulatory compliance.

Frequently Asked Questions

1. Are there any active patents that could restrict the manufacturing of Iloperidone API? The primary composition of matter patent has expired, opening the market. However, specific process patents or patents on novel polymorphic forms might exist, influencing manufacturing methods for some companies.
2. What are the main quality concerns when sourcing Iloperidone API? Key concerns include the control of process-related impurities, residual solvents, and ensuring batch-to-batch consistency. Meeting pharmacopeial specifications (USP, EP) and maintaining validated analytical methods are crucial.
3. How can a company ensure a reliable supply of Iloperidone API amidst potential geopolitical disruptions? Implementing dual sourcing strategies, qualifying manufacturers in different geographic regions, and maintaining adequate safety stock are essential risk mitigation measures.
4. What is the typical lead time for ordering large quantities of Iloperidone API from Asian manufacturers? Lead times can vary but generally range from 8 to 16 weeks for bulk orders, depending on the manufacturer's current production schedule, order volume, and the need for specialized testing or documentation.
5. Does the cost of Iloperidone API include regulatory filing support, such as DMF updates? While basic DMF support is usually included, significant updates, amendments, or assistance with specific client regulatory filings often incur additional costs. This should be explicitly clarified in supply agreements.

Citations

[1] U.S. Food & Drug Administration. (n.d.). U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/ [2] European Medicines Agency. (n.d.). European Medicines Agency. Retrieved from https://www.ema.europa.eu/ [3] World Health Organization. (n.d.). World Health Organization. Retrieved from https://www.who.int/ [4] Market research reports on pharmaceutical APIs (proprietary data not publicly available). [5] Publicly available company information and annual reports from listed manufacturers.